Private Equity Firm Financial Services

Deep Track Capital

United States

Private investment management firm investing in private companies (including healthcare/life sciences) and participating in private placement financing such as PIPE transactions.

Focus Areas
Private equity / investment management, Healthcare / life sciences investing

Tracked deals

3

3 tracked deals across 2026.

Recent pace

3

3 tracked deals announced in the last 12 months.

Deal mix

Buyout

2 buyout · 1 growth capital

Deep Track Capital Acquisition Volume by Year

Last 1 years

Acquisition volume by year Annual acquisition counts for the last 1 years for Deep Track Capital. ~4 est. 3 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Investor Group Provides $120 Million Private Placement to Bolt Biotherapeutics
    October 24, 2026
    Buyer
    Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital, YK Bioventures
    Target
    Bolt Biotherapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Growth capital

    Bolt Biotherapeutics secured a concurrent $120 million private placement from Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital, and YK Bioventures. The financing is intended to fund Bolt’s operations into 2028 and advance PRA-216 and other pipeline programs; warrants could provide an additional $60 million.

  • Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp
    June 29, 2026
    Buyer
    JATT II Acquisition Corp, Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, JATT Ventures II L.P.
    Target
    Talawar Therapeutics, Talawar Tx Inc
    Industry
    Biotechnology
    Location
    New Jersey, United States
    Type
    Buyout

    Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

  • InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M All-Stock Deal
    May 20, 2026
    Buyer
    InMed Pharmaceuticals, Inc., Fairmount, Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, Vivo Capital, Perceptive Advisors, Sirenia Capital Management LP, Oruka Therapeutics (Oruka Therapeutics executive board involvement)
    Target
    Mentari Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    InMed Pharmaceuticals (NASDAQ: INM) entered into a definitive all-stock merger agreement with privately held Mentari Therapeutics, creating a publicly traded migraine-focused biotech under the Mentari name. The transaction is supported by an oversubscribed $290 million private placement led by Fairmount to fund operations through 2028.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Deep Track Capital. Acquisitions in California 1 tracked deal by Deep Track Capital. Acquisitions in New Jersey 1 tracked deal by Deep Track Capital.

Related articles

Selling a company? Get in front of buyers like Deep Track Capital

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →